NCT03874689 (TEPIM) is a clinical trial in Neurocysticercosis, sponsored by Technical University of Munich.

Who is sponsoring NCT03874689?

NCT03874689 is sponsored by Technical University of Munich.

What condition does NCT03874689 study?

NCT03874689 studies Neurocysticercosis, Taeniosis.

Is NCT03874689 still recruiting?

NCT03874689 is currently completed. Last updated 30 November 2023.

Last reviewed 2023-11-30 · How we verify

NCT03874689: TEPIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia

Completed Last updated 30 November 2023

What this trial tests

trial in Neurocysticercosis in 2,921 participants. Completed in 31 December 2022.

Timeline

1 June 2019

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Technical University of Munich
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,921
Start date	1 June 2019
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Zambia

Conditions studied

Neurocysticercosis — all drugs for Neurocysticercosis →
Taeniosis — all drugs for Taeniosis →

Sponsor

Technical University of Munich

Who can join

10 and older, any sex, with Neurocysticercosis or Taeniosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine the prevalence of taeniosis and (neuro)cysticercosis in two districts in the southern (Gwembe) and eastern province (Chipata) of Zambia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neurocysticercosis

Currently open trials in the same condition.

NCT00001205 — Natural History of Treated Neurocysticercosis and Long-Term Outcomes · recruiting

Other Technical University of Munich trials

Trials by the same sponsor.

NCT07519811 — LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
NCT07077005 — Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy · NA · recruiting
NCT07212699 — Development of an Outcome Score for Patients With Knee Osteoarthritis and Knee Joint Endoprosthesis Using an App · NA · recruiting
NCT06823271 — Haemodynamics and Ventricular Arrhythmias During Exercise in Patients With Arrhythmogenic Cardiomyopathy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03874689 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Technical University of Munich
Last refreshed: 30 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03874689.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing